# Clarametyx Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/clarametyx-biosciences

- Industry: Pharmaceuticals
- Headquarters: Columbus, US
- Website: www.clarametyx.com
- Total disclosed funding: $28M
- Latest round: Series A (Jan 28, 2025)
- Investors on record: 9

## About

Based in Ohio, US, and founded in 2020 by CEO David Richards, Clarametyx Biosciences Inc. operates as a pharmaceutical research and development company developing vaccine that enables the human body to prevent the biofilm barrier to develop. In January 2024, Clarametyx Biosciences Inc. raised USD 33 million in Series A funding led by Ohio Innovation Fund, with participation from Rev1 Ventures. 

Clarametyx Biosciences Inc. developed a technology platform, which is a pathogen-agnostic that can be applied to a wide range of bacterial infections, known as CMTX-101. The company is also developing CMTX-301, which is a vaccine in pre-clinical development aimed at preventing biofilm formation by triggering an immune response to key biofilm proteins. In addition, the firm focuses on developing new treatments against persistent bacterial infections, with initial applications targeting respiratory tract infections and chronic diseases like cystic fibrosis.

The company plans to use the funding from January 2024 to accelerate efforts across its pipeline, including specifically to evaluate the potential of its lead therapeutic candidate CMTX-101 to combat infection in people with cystic fibrosis (CF), a progressive, genetic disease that affects the lungs, pancreas and other organs.

## Funding rounds

- Series A, Jan 28, 2025 — Kineticos Ventures
- Series A, Jan 5, 2024, $28M — Ohio Innovation Fund, Cystic Fibrosis Foundation, Rev1 Ventures, 1776, JobsOhio, Nationwide Children’s Hospital, C Bio Investors
- Seed, May 4, 2020 — Ohio Innovation Fund, Rev1 Ventures, Emerald Shoals Targeted Opportunities Fund

## Investors

- Ohio Innovation Fund (https://capitalatlas.ai/funds/ohio-innovation-fund) — Seed, Series A
- Rev1 Ventures (https://capitalatlas.ai/funds/rev1-ventures) — Seed, Series A
- Emerald Shoals Targeted Opportunities Fund (https://capitalatlas.ai/funds/emerald-shoals-targeted-opportunities-fund) — Seed
- Cystic Fibrosis Foundation — Series A
- 1776 (https://capitalatlas.ai/funds/1776) — Series A
- JobsOhio (https://capitalatlas.ai/funds/jobsohio) — Series A
- Nationwide Children’s Hospital — Series A
- C Bio Investors — Series A
- Kineticos Ventures (https://capitalatlas.ai/funds/kineticos-ventures) — Series A